None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Men and women over 40 years old but under 70 years old 2) Those with Kellgren-Lawrence grade 2 or 3 on knee joint radiography 3) Those diagnosed with knee osteoarthritis according to the ACR (American College of Rheumatology criteria) diagnostic criteria 4) Those who receive minimal help regarding their pain, are able to communicate sufficiently with the researcher, and are able to fill out the questionnaire. 5) Those who voluntarily agreed to participate in this clinical trial
Exclusion criteria
Exclusion criteria: 1) Patients with a history of knee joint trauma or surgery on the knee joint within 6 months from the time of screening 2) Patients who have received intra-articular injection treatment within 6 months from the time of screening (steroids, hyaluronic acid, etc.) 3) Patients who are suspected to have following diseases in physical examination and diagnostic examination: rheumatoid arthritis, autoimmune disease, septic arthritis, inflammatory joint disease, fibromyalgia 4) Patients receiving treatment for mental disorders such as depression and schizophrenia 5) Patients with other diseases that may interfere with treatment, such as serious gastrointestinal or cardiovascular diseases, uncontrolled hypertension or diabetes, serious kidney or liver diseases, or hemorrhagic diseases 6) Patients who have concomitant diseases which is prohibited to prescribe non-steroidal anti-inflammatory painkillers, hypersensitivity reactions to non-steroidal anti-inflammatory painkillers, and who have taken concomitant drugs. 7) Pregnant and lactating women 8) Participants whose participation in clinical research is determined to be difficult at the discretion of the research staff
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Korean version of Western Ontario and McMaster Scale (KWOMAC) | — |
Secondary
| Measure | Time frame |
|---|---|
| 100mm pain VAS;EQ-5D-5L;Treatment satisfaction evaluation;Employee satisfaction evaluation;Adverse event;Laboratory test;Vital sign;Change of the concomitant drug | — |
Countries
Korea, Republic of
Contacts
Kyung Hee University Oriental Medicine Hospital at Gangdong